^
Association details:
Evidence:
Evidence Level:
Sensitive: C4 – Case Studies
New
Title:

HER2 mutated breast cancer responds to treatment with single agent neratinib, a second generation HER2/EGFR tyrosine kinase inhibitor

Excerpt:
This patient’s cancer had a HER2 L755S mutation....After 11 months, her cancer progressed and treatment with neratinib plus capecitabine produced another disease response...
Secondary therapy:
capecitabine
DOI:
https://doi.org/10.6004/jnccn.2015.0131
Evidence Level:
Sensitive: C4 – Case Studies
New
Title:

HER2 mutated breast cancer responds to treatment with single agent neratinib, a second generation HER2/EGFR tyrosine kinase inhibitor

Excerpt:
This patient’s cancer had a HER2 L755S mutation and she had a partial response from neratinib monotherapy. This response markedly improved the patient’s performance status and quality of life.
DOI:
https://doi.org/10.6004/jnccn.2015.0131